Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.

about

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.

Item

http://www.wikidata.org/entity/Q49643911

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cis-oriented solvent-front EGF ...... and review of the literature.

@en

Cis-oriented solvent-front EGF ...... and review of the literature.

@nl

type

Item

label

Cis-oriented solvent-front EGF ...... and review of the literature.

@en

Cis-oriented solvent-front EGF ...... and review of the literature.

@nl

prefLabel

Cis-oriented solvent-front EGF ...... and review of the literature.

@en

Cis-oriented solvent-front EGF ...... and review of the literature.

@nl

P1476

Cis-oriented solvent-front EGF ...... t and review of the literature

@en

P2093

Alexa B Schrock

http://www.w3.org/2001/XMLSchema#string

Pareen Mehta

http://www.w3.org/2001/XMLSchema#string

Sai-Hong Ignatius Ou

http://www.w3.org/2001/XMLSchema#string

Siraj M Ali

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

P304

241-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2147/LCTT.S147129

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Samuel J Klempner

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29255376

http://www.w3.org/2001/XMLSchema#string

P932

5723122

http://www.w3.org/2001/XMLSchema#string